Jennison Associates’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-138,388
| Closed | -$16.8M | – | 623 |
|
|
2023
Q3 | $16.8M | Buy |
138,388
+1,148
| +0.8% | +$130K | 0.01% | 331 |
|
|
2023
Q2 | $15.7M | Buy |
137,240
+16,979
| +14% | +$2.19M | 0.01% | 341 |
|
|
2023
Q1 | $16.6M | Buy |
+120,261
| New | +$15.6M | 0.02% | 347 |
|
|
2022
Q1 | – | Sell |
-304,735
| Closed | -$27.4M | – | 699 |
|
|
2021
Q4 | $27.4M | Buy |
304,735
+250,274
| +460% | +$21.4M | 0.02% | 311 |
|
|
2021
Q3 | $5.04M | Sell |
54,461
-7,668
| -12% | -$591K | ﹤0.01% | 483 |
|
|
2021
Q2 | $4.83M | Sell |
62,129
-4
| -0% | -$303 | ﹤0.01% | 498 |
|
|
2021
Q1 | $4.63M | Sell |
62,133
-2,365,759
| -97% | -$218M | ﹤0.01% | 482 |
|
|
2020
Q4 | $414M | Sell |
2,427,892
-177,180
| -7% | -$26.3M | 0.3% | 53 |
|
|
2020
Q3 | $366M | Buy |
2,605,072
+2,021,091
| +346% | +$307M | 0.29% | 50 |
|
|
2020
Q2 | $93.6M | Sell |
583,981
-191,939
| -25% | -$26.1M | 0.08% | 98 |
|
|
2020
Q1 | $75.9M | Buy |
775,920
+5,909
| +0.8% | +$675K | 0.09% | 96 |
|
|
2019
Q4 | $99.4M | Sell |
770,011
-329,682
| -30% | -$33.3M | 0.1% | 109 |
|
|
2019
Q3 | $82.8M | Buy |
1,099,693
+99,394
| +10% | +$11.7M | 0.09% | 132 |
|
|
2019
Q2 | $152M | Sell |
1,000,299
-7,180
| -0.7% | -$873K | 0.15% | 82 |
|
|
2019
Q1 | $120M | Sell |
1,007,479
-15,036
| -1% | -$1.93M | 0.12% | 100 |
|
|
2018
Q4 | $112M | Sell |
1,022,515
-196,988
| -16% | -$24.6M | 0.12% | 98 |
|
|
2018
Q3 | $197M | Buy |
1,219,503
+5,604
| +0.5% | +$766K | 0.18% | 71 |
|
|
2018
Q2 | $160M | Sell |
1,213,899
-113,104
| -9% | -$10.7M | 0.16% | 84 |
|
|
2018
Q1 | $98.3M | Buy |
1,327,003
+176,793
| +15% | +$11.8M | 0.1% | 154 |
|
|
2017
Q4 | $64M | Buy |
1,150,210
+6,357
| +0.6% | +$337K | 0.06% | 229 |
|
|
2017
Q3 | $51.9M | Buy |
1,143,853
+582,894
| +104% | +$23.3M | 0.05% | 265 |
|
|
2017
Q2 | $18.9M | Sell |
560,959
-2,374
| -0.4% | -$77.3K | 0.02% | 418 |
|
|
2017
Q1 | $16.7M | Hold |
563,333
| – | – | 0.02% | 444 |
|
|
2016
Q4 | $15.5M | Sell |
563,333
-830,455
| -60% | -$33.4M | 0.02% | 443 |
|
|
2016
Q3 | $85.6M | Buy |
1,393,788
+348,130
| +33% | +$10.5M | 0.09% | 191 |
|
|
2016
Q2 | $19.9M | Buy |
+1,045,658
| New | +$19.4M | 0.02% | 403 |
|
|
2016
Q1 | – | Sell |
-838,629
| Closed | -$32.4M | – | 657 |
|
|
2015
Q4 | $32.4M | Buy |
838,629
+689,831
| +464% | +$22.4M | 0.03% | 359 |
|
|
2015
Q3 | $4.78M | Sell |
148,798
-204,202
| -58% | -$6.93M | ﹤0.01% | 542 |
|
|
2015
Q2 | $10.7M | Buy |
+353,000
| New | +$7.22M | 0.01% | 511 |
|
|
2014
Q4 | – | Sell |
-1,023,834
| Closed | -$21.6M | – | 753 |
|
|
2014
Q3 | $21.6M | Buy |
+1,023,834
| New | +$23.1M | 0.02% | 427 |
|
Other funds holding SRPT
ACA
Jennison Associates's SRPT Position: Q4 2023 in Review
Jennison Associates sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 138,388 shares — an estimated $16.8M sold.
Jennison Associates first reported a position in SRPT in Q3 2014 and held it in 30 quarters. The position peaked at $414M in Q4 2020. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.
- Jennison Associates reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
- Jennison Associates sold 138,388 Sarepta Therapeutics shares in Q4 2023, an estimated $16.8M.
- Jennison Associates first reported a position in Sarepta Therapeutics in Q3 2014 and held it in 30 quarters.
- Jennison Associates's Sarepta Therapeutics position peaked at $414M in Q4 2020.
- 395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.
Based on Jennison Associates's 13F filing for Q4 2023, filed 1 Feb 2024.